CTOs on the Move

Care Fusion

www.enturia.com

 
Care Fusion is a Leawood, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enturia.com
  • 11400 Tomahawk Creek Pkwy
    Leawood, KS USA 66211
  • Phone: 913.451.0880

Executives

Name Title Contact Details

Similar Companies

Nucletron

Nucletron Corp. is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Biopsy

Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. For the first time, this unique ability will eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease. The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate.

Ocularvision

Ocularvision is a Buellton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedManage Systems

MedManage Systems is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.